VYNE Therapeutics (VYNE) Non-Current Deffered Revenue (2016 - 2018)

VYNE Therapeutics' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $6.3 million for Q1 2018.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $6.3 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $6.3 million (changed N/A YoY) and the FY2017 annual result came in at $6.7 million, down 21.05% from the prior year.
• Non-Current Deffered Revenue was $6.3 million for Q1 2018 at VYNE Therapeutics, down from $6.7 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $8.5 million in Q4 2016 and bottomed at $6.3 million in Q1 2018.
• A 3-year average of $7.2 million and a median of $6.7 million in 2017 frame the typical range for Non-Current Deffered Revenue.
• Peak annual rise in Non-Current Deffered Revenue reached 21.05% in 2017, while the deepest fall reached 21.05% in 2017.
• VYNE Therapeutics' Non-Current Deffered Revenue stood at $8.5 million in 2016, then slipped by 21.05% to $6.7 million in 2017, then declined by 6.67% to $6.3 million in 2018.
• Business Quant data shows VYNE's Non-Current Deffered Revenue at $6.3 million in Q1 2018, $6.7 million in Q4 2017, and $8.5 million in Q4 2016.